← board
BETRF
distress 7/10 · high distress / dilution risk$0.170%today0% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
+326%
Price & events
+388.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+3.6%
1W
+200.0%
1M
+249.0%
3M
+388.6%
6M
+163.1%
1Y
+42.5%
2Y
-30.5%
5Y
-90.1%
All
Overview
- Market Cap
- $24.88M
- Enterprise Value
- $24.88M
- Volume
- 115.80K
- 52 Week Range
- $0.03 – $0.17
- Total Shares
- 145.49M
- Float Shares
- 107.71M
- % Held by Insiders
- 33.79%
- % Held by Institutions
- 0.00%
- RVOL
- 0.73x
- Beta
- 0.28
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 145,494,883 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.